<DOC>
	<DOCNO>NCT00595920</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Tovaxin treatment relapse form multiple sclerosis .</brief_summary>
	<brief_title>Open Label Extension Prior TERMS Study Treat Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description>The subject positive myelin-reactive T cell ( MRTC ) blood previous TERMS study immediately eligible Tovaxin production treatment open label extension study . The MRTC negative subject monitor quarterly safety , MRTC reactivity , paraclinical clinical effect . Subjects become MRTC positive monitoring phase eligible Tovaxin production treatment study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects complete TERMS study receive least 1 study treatment injection Signed dated statement inform consent Pregnancy breastfeeding Experienced serious adverse drug reaction confirmatory relationship Tovaxin TERMS study . Withdrew TERMS study continue participate remain 52week core TERMS study assessment . Noncompliant TERMS study . Diagnosis progressiverelapsing , secondary progressive primary progressive Multiple Sclerosis ( MS ) enrol TERMS study . Medical , psychiatric condition compromise subject 's ability give inform consent , understand patient information , comply study protocol , complete study . Any significant change subject 's medical condition enrollment TERMS study would lead his/her exclusion participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Tovaxin</keyword>
	<keyword>Autologous</keyword>
	<keyword>T-cell vaccine ( TCV )</keyword>
</DOC>